↓ Skip to main content

Dove Medical Press

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date

Overview of attention for article published in Drug Design, Development and Therapy, September 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

policy
1 policy source
twitter
4 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
10 Mendeley
Title
An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
Published in
Drug Design, Development and Therapy, September 2021
DOI 10.2147/dddt.s281614
Pubmed ID
Authors

Umut Yilmaz, Ayse Salihoglu, Teoman Soysal

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 40%
Student > Master 1 10%
Unknown 5 50%
Readers by discipline Count As %
Medicine and Dentistry 4 40%
Economics, Econometrics and Finance 1 10%
Unspecified 1 10%
Unknown 4 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2021.
All research outputs
#6,280,996
of 25,392,582 outputs
Outputs from Drug Design, Development and Therapy
#406
of 2,269 outputs
Outputs of similar age
#118,284
of 433,636 outputs
Outputs of similar age from Drug Design, Development and Therapy
#7
of 41 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,269 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 433,636 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.